Relay Therapeutics has traded in a relatively contained range in recent weeks, with shares hovering near $18 and a market capitalization of roughly $4 billion. The stock's 30-day move of approximately 4.6% reflects a period of consolidation rather than a sharp breakout, as investors weigh near-term clinical catalysts against the company's status as a pre-revenue biotechnology firm. Broader biotech sentiment has remained constructive, and RLAY's elevated beta means the shares can amplify both sector-wide rallies and risk-off episodes. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company focused on oncology and genetic disease. Its core technology, the Dynamo platform, integrates computational chemistry, structural biology, and biophysics to target proteins that have historically been difficult to drug. The company's lead program, zovegalisib, is described as the first pan-mutant, isoform-selective PI3Kα inhibitor to enter clinical development, positioning it as a potential differentiated therapy for PIK3CA-mutated cancers and vascular anomalies. The broader pipeline includes RLY-8161, an NRAS-selective inhibitor, a Fabry disease program, and a mutant-selective TIE2 inhibitor. Relay's out-licensed asset, lirafugratinib (RLY-4008), has been partnered with Elevar Therapeutics, which received full approval for the therapy in FGFR2-fusion cholangiocarcinoma. Investors follow RLAY for its late-stage oncology readouts and the commercial potential of zovegalisib across large patient populations.
Relay reported third-quarter 2026 results on November 4, posting a narrower-than-expected loss per share that modestly beat consensus. The company ended the quarter with approximately $849 million in cash, cash equivalents, and investments, which it expects will fund operations into 2029. Management highlighted faster-than-anticipated enrollment in the Phase 3 ReDiscover-2 trial, now estimated to complete enrollment in mid-2027, and announced updated ReInspire data and a regulatory update planned for the ASH Annual Meeting on December 14, 2026. The company also appointed a new head of commercial, signaling preparations for a potential transition toward commercialization. During the period, analysts maintained a broadly positive stance, with a consensus Strong Buy rating. These pipeline and financial updates have supported investor confidence, while the absence of major clinical data readouts in the immediate window has kept price action relatively measured. From what I see, the cash position provides meaningful runway that reduces near-term financing risk.
Looking ahead, the most significant near-term catalyst for Relay is the updated vascular anomalies dataset and accompanying regulatory update scheduled for the ASH Annual Meeting in December 2026. Beyond that, investors will monitor continued enrollment progress in the Phase 3 ReDiscover-2 trial, the regulatory confirmation of the frontline breast cancer trial design expected by year-end 2026, and the planned initiation of a Phase 3 frontline study in early 2027. The company's partnership with Pfizer (PFE) for supply of atirmociclib and palbociclib in the frontline setting also warrants attention. As a pre-revenue developer, Relay's outlook remains tied to clinical execution, cash runway management, and regulatory milestones rather than near-term earnings growth, and the shares may remain sensitive to broader biotech sentiment and sector rotation. I'm watching this closely as execution on these milestones could drive meaningful re-rating potential.
One tool I find particularly useful for spotting systematic strategies is Tickeron’s Trending AI Robots. It curates top-performing bots across thousands of tickers, helping me identify approaches that are gaining traction without having to sift through everything manually. The section offers a range of quantitative strategies that complement traditional fundamental analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RLAY advanced for three days, in 237 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for RLAY just turned positive on November 09, 2026. Looking at past instances where RLAY's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
The 10-day moving average for RLAY crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 181 of 228 cases where RLAY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 53 cases where RLAY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RLAY as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
RLAY moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
RLAY broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.580) is normal, around the industry mean (3.498). P/E Ratio (-11.923) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RLAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets
Industry Biotechnology